CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy.
Alemtuzumab has been proposed as a therapeutic agent in myeloma. CD52 was detected on plasma cells in 46/106 patients but levels were 30-fold lower than on alemtuzumab-responsive cells (n=138) and 8-fold lower than on alemtuzumab-resistant cells (n=57). The data suggest that myeloma plasma cells are unlikely to be depleted by alemtuzumab in most patients.
Rawstron
Andy C
AC
Laycock-Brown
Giles
G
Hale
Geoff
G
Davies
Faith E
FE
Morgan
Gareth J
GJ
Child
J Anthony
JA
Hillmen
Peter
P
Owen
Roger G
RG
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D015703:Antigens, CD / Q000096:biosynthesis* / Q000235:genetics*; D000951:Antigens, Neoplasm / Q000096:biosynthesis* / Q000235:genetics*; D000074301:CD52 Antigen; D015972:Gene Expression Regulation, Neoplastic / Q000276:immunology; D006023:Glycoproteins / Q000096:biosynthesis* / Q000235:genetics*; D006801:Humans; D009101:Multiple Myeloma / Q000235:genetics / Q000378:metabolism* / Q000628:therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins; D000074323:Alemtuzumab